The Access to Cannabis for Medical Purposes Regulations (ACMPR) contain four parts:
Part 1 is similar to the framework under the MMPR. It sets out a framework for commercial production by licensed producers responsible for the production and distribution of quality-controlled fresh or dried marijuana or cannabis oil or starting materials (i.e., marijuana seeds and plants) in secure and sanitary conditions.
Part 2 is similar to the former MMAR regime. It sets out provisions for individuals to produce a limited amount of cannabis for their own medical purposes or to designate someone to produce it for them.
Parts 3 and 4 include:
Transitional provisions, which mainly relate to the continuation of MMPR activities by licensed producers.
Consequential amendments to other regulations that referenced the MMPR (i.e., Narcotic Control Regulations, New Classes of Practitioners Regulations) to update definitions and broaden the scope of products beyond dried marijuana.
Provisions repealing the MMPR and setting out the coming into force of the ACMPR on August 24, 2016.
Health Canada is now accepting applications from individuals who wish to register to produce a limited amount of cannabis for their own medical purposes or to designate someone to produce cannabis for them, whilst Health Canada will continue to accept and process applications to become a licensed producer that were submitted under the former MMPR.
Furthermore, all licences and security clearances granted under the MMPR will continue under the ACMPR, which means that licensed producers can continue to register and supply clients with cannabis for medical purposes. New applicants can continue to apply for licences to produce medical marihuana under the ACMPR.
The Licensed producers (LPs) under the ACMPR shall still be subject to regulatory requirements related to security; good production practices (GPP); packaging, labelling and shipping; record keeping and reporting; and distribution. Prior to the issuance of a licensed producer license the site will be subject to Health Canada inspections.
ARA – Avanti Rx Analytics can prepare or help you to prepare your application to become a licensed producer under the new ACMPR regulation and provide expert guidance on how to meet the security, record keeping, prepare the Quality Assurance Report (QAR), and GPP requirements, including the preparation of the Standard Operating Procedures (SOPs) and quality manual.
Our QA and Regulatory experts comprise a powerful blend of consultants with Health Canada, FDA, and industry experience including leading scientific and technical experts whose guidance and recommendation are not only scientifically and technically accurate, but also actionable.
We work with our clients to design and implement effective, efficient, and current processes that assures sustainable compliance by integration of scientific, technical, and regulatory principles.
At ARA, we work with businesses that are focused on the progress of medical marijuana industry, as against those who work solely for profit motive. Our team will help your business to achieve its goals while adhering by the laws that govern the marijuana or cannabis trade at different levels.
The consulting services offered by ARA – Avanti Rx Analytics include:
Based on our proprietary state-of-the-art technology, we can help our clients in designing and implementing productive indoor cannabis cultivation facilities. Our years of experience and knowledge of the marijuana industry help us create optimum growth rooms for your crops and make them reach their full potential.
After identifying ideal space and surrounding area for your cultivation, we will work with you to implement an innovative crop growing facility. We can direct architectural and mechanical design as well as sourcing the suitable equipment required for successful indoor cultivation whilst meeting the compliance requirements for your licence.
Assisting our clients to obtain their Health Canada Licence for production of medical marihuana is one of our major services that includes:
Helping to interpret MMPR regulations in concert with industry standards
Preparation and submission of ACMPR application to Health Canada
Participation in Health Canada audits of client’s facility and systems
Evaluate and facilitate the resolution of complex exclusivity issues involving MMPR application and related regulatory and compliance issues to ensure timely approval process
Preparation and evaluation of written procedures, policies, and standard operating procedures (SOPs)
Preparation of Quality Report
Creating a program to meet current Health Canada’s expectations for GPP Compliance
Provide expert scientific guidance to understand and resolve significant issues related to any regulatory observations and warning letters in order to ensure timely resolution of complicated scientific, technical, and/or compliance issues raised by Health Canada application reviewer.
Develop and deliver specialized hands on trainings
Reviewing and enhancing management controls
Performed due diligence audits of applications in association with the MMPR regulation
Provide expert consultant services for development and execution of numerous remediation/voluntary corrective action plans, which have been accepted by the Health Canada
Facilitation of a new facility construction review/s for clients with the Health Canada
|1||Standard Operating Procedures (SOPs)|
|2||Employee Training Program|
|3||Employee Health and Safety|
|5||Good Documentation Practices|
|7||Change Control (CC) Program|
|8||Investigation of Out of Specification (OOS) Results|
|9||Deviation Management Program|
|10||Corrective and Preventative Action (CAPA)|
|11||Product Complaints Program|
|12||The Operational Variance Report (OVR) Program|
|13||Product Recall Program|
|14||Post – Market Surveillance|
|15||Qualified Person in Charge (QPIC)|
|16||Good Production Practices (GPP)|
|17||Responsibilities of the Quality Unit and Personnel|
|19||Senior Responsible Person in Charge (ARPIC) and Responsible Person in Charge (RPIC)|
|22||Equipment Calibration and Maintenance|
|23||Validation of Computerized Systems|
|25||Analytical Method Validation|
|26||Medical Marijuana Product Specification|
|27||Analysis of Medical Marijuana|
|28||Material Receiving, Handling, Sampling and Testing|
|29||Disposition (release) of Finished Products|
|30||Retained Samples Policy|
|31||Product Over Labelling|
|32||Orders and Distribution Records|
|34||Warehousing/Material Management/Inventory Controls|
|35||Handing of Damaged and Returned Products|
|36||Security Measures for Handling Medical Marihuana|
|37||Medical Marihuana Storage|
|38||Destruction of Marihuana Plant Waste|
|39||Facility Maintenance and Sanitation|
|40||Facility Security and Security Access|
|41||Environmental Controls: Air Handling (HVAC) and Water System|
|42||Facility Pest Control Program|
|44||Medical Marihuana Transportation|